Coronavirus Disease 2019 (COVID-19) Vaccines – Opportunity Assessment and Forecast to 2026
- Pages: 73
- Published: June 2021
- Report Code: GDHCOA006
The first COVID-19 vaccines received Emergency Use Authorization (EUA) in December 2020. Thus, the COVID-19 vaccine market is in a very early stage, but many vaccines have been authorized or approved to date, and more than 110 are in clinical development. Globally, in most countries COVID-19 vaccine demand still largely outstrips supply.However, the US now has an excess of COVID-19 vaccine doses, while demand is still higher than supply in the EU and vaccination is still at avery early stage in Japan. The COVID-19 vaccine landscape is still characterized by a high level of unmet need, both clinically and with regard to vaccine supply
Currently authorized/approved COVID-19 vaccines in the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) include highly efficacious vaccines from Pfizer/BioNTech and Moderna, and adenovirus vector-based vaccines from AstraZeneca and J&J.
The Coronavirus Disease 2019 (COVID-19) Vaccines – Opportunity Assessment and Forecast to 2026 gives a COVID-19 disease overview, epidemiology overview, current marketed vaccines, unmet needs, pipeline assessment, and market outlook. Report deliverables include a PowerPoint report and an interactive Excel-based forecast model which includes 7MM (US, France, Germany, Italy, Spain, UK, and Japan) with forecasts over 5 years from 2021 to 2026.
This report includes:
- Executive Summary
- Disease Overview: History of the outbreak, Etiology and Pathophysiology
- Current Vaccination Options: Includes detailed product profiles with SWOT analysis
- Unmet Need and Opportunities: Detailing the major unmet needs with significant KOL insights
- Pipeline Assessment: Includes pipeline overview and detailed product profiles with SWOT analysis
- R&D Strategies: Trends in Clinical Trial Design for COVID-19 Vaccines and Trends in Deal-Making
GlobalData forecast three different potential scenarios for the future use of COVID-19 vaccines:
- The first scenario assumes that annual vaccination with a COVID-19 vaccine will be needed.
- The second scenario assumes annual vaccination for the high-risk population of people 65 years of age and older, while everyone below 65 years of age will need a vaccine only every two years.
- In the third scenario, the high-risk population of people 65 years of age and older will receive a COVID-19 vaccine every two years, while everyone below 65 years will need a vaccine only every five years.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM COVID-19 vaccine.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global COVID-19 vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Pfizer, BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, CureVac, Sanofi, GlaxoSmithKline, Arcturus, Medicago, Valneva, Inovio
Table of Contents
Table of Contents (PowerPoint Deck)
1 Executive Summary
2 Disease Overview
4 Current Vaccination Options
5 Unmet Needs and Opportunities
6 Pipeline Assessment
7 R&D Strategies
8 Market Outlook
10 Contact Us